08-Methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma
1998

MGMT Levels and Response to Temozolomide in Melanoma

Sample size: 56 publication Evidence: low

Author Information

Author(s): MR Middleton, JM Lunn, C Morris, G Rustin, SR Wedge, MH Brampton, MJ Lind, SM Lee, DR Newell, NM Bleehen, ES Newlands, AH Calvert, GP Margison, N Thatcher

Hypothesis

The study investigates whether pretreatment levels of MGMT in melanoma biopsies can predict response to temozolomide treatment.

Conclusion

Measurements of pretreatment levels of MGMT in melanoma did not predict for response to temozolomide.

Supporting Evidence

  • Among 50 evaluable patients, there were three complete responses, four partial responses, six with stable disease, and 37 with progressive disease.
  • The overall response rate was 14%.
  • In 33 patients, there was no significant difference in pretreatment MGMT levels between those who responded to temozolomide and those who did not.

Takeaway

The study looked at whether a certain protein level in melanoma tumors could help doctors know if a medicine would work, but it turns out it doesn't help at all.

Methodology

Patients with advanced melanoma were treated with temozolomide, and their tumor MGMT levels were measured to see if there was a correlation with treatment response.

Limitations

The study had a small sample size and included patients with prior chemotherapy, which may have affected the results.

Participant Demographics

56 patients, 46% men and 54% women, with a WHO performance status of 0 to 3.

Statistical Information

P-Value

0.95

Statistical Significance

p = 0.95

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication